Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)

Learn more about:
Related Clinical Trial
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome Development of the ORCA Communication Measure for Rett Syndrome The Rett Syndrome Global Registry Open-Label Extension Study of Trofinetide for Rett Syndrome ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME Predictors of Caregiver Adaptation to Pervasive Developmental Disorders A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 Study in Patients With Rett Syndrome Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome Nutritional Aspects of Rett Syndrome Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW Study of the Pathogenesis of Rett Syndrome Advanced Grandparental Age as a Risk Factor for Autism A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Biobanking of Rett Syndrome and Related Disorders Telehealth Support to Increase Physical Activity in Rett Syndrome Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Natural History of Rett Syndrome & Related Disorders Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome Study of ANAVEX2-73 in Patients With Rett Syndrome Trial of Dextromethorphan in Rett Syndrome Pharmacological Treatment of Rett Syndrome With Statins An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome Analysis of the Glutathione Cycle in Children With Rett Syndrome Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ‘Uptime’ Participation Intervention in Girls and Women With Rett Syndrome Functional Abilities in Rett Syndrome Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Placebo Controlled Trial of Dextromethorphan in Rett Syndrome Effects of Creatine Supplementation in Rett Syndrome Metabolic Evaluation of Nutrition in Rett Syndrome Treatment of Rett Syndrome With Recombinant Human IGF-1 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms A Safety Study of NNZ-2566 in Patients With Rett Syndrome Genetic and Physical Characteristics of Rett Syndrome Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome The Findings of MR Imaging in Rett Syndrome Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Patients With RETT Syndrome Creatine Metabolism in Rett Syndrome

Brief Title

Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)

Official Title

Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With IGF-1

Brief Summary

      The investigators are recruiting children for a research study using a medication known as
      IGF-1 (mecasermin or INCRELEX) to see if it improves the health of children with Rett
      syndrome (RTT). To participate in the study your child must be female, between the ages of 2
      to 12 and have a genetic diagnosis (MECP2 deletion or mutation) of Rett Syndrome. As you may
      know, there is no treatment for this illness. Currently, the standard management of Rett
      syndrome is supportive, which means attempting to prevent complications and treatment of
      symptoms.

      This study involves testing an investigational drug, which means that even though IGF-1 is
      approved by the Food and Drug Administration (FDA) for use in children, it has not been used
      before to treat Rett syndrome specifically. Information from this research will help
      determine whether the drug should be approved by the FDA in the future for the treatment of
      Rett Syndrome.

      There are five major goals to this study:

        1. As one of the features of Rett Syndrome is unstable vital signs, the investigators are
           trying to determine if IGF-1 has any effect on normalizing your child's pulse, blood
           pressure and breathing pattern.

        2. The safety of IGF-1 in children with Rett syndrome. The study personnel will ask you to
           complete a medication diary and side effect reporting form on a regular basis. They will
           assist you in completing this by telephone interviews. Your child will undergo 2 lumbar
           punctures performed at the bedside in the clinical research facility. In addition,
           laboratory tests will be performed throughout the study to evaluate the safety of IGF-1.
           These will be blood tests similar to those provided in routine clinical care. Your child
           will undergo regular non-invasive comprehensive physical examinations including
           neurological and eye examination, tonsil evaluation, electrocardiograms (ECG),
           measurement of height, weight and head circumference.

        3. IGF-1 may improve your child's behavior, communication and speech. In order to measure
           this, the investigators will evaluate your child once during each month of treatment
           with neurodevelopmental assessments and a neurological exam. Investigators will also ask
           you about her behavior and day-to-day functioning through a structured parental
           interview and questionnaires.

        4. We will examine your child's cortical function through use of electroencephalography
           (EEG) in conjunction with presentation of visual and auditory stimuli. EEG is a
           non-invasive way of recording the electrical activity of your child's brain.

        5. Children with Rett Syndrome sometimes experience "flushing" in their cheeks or have
           exceptionally cold hands or feet and/or abnormal perspiration. The Qsensor® is a
           non-invasive device worn on a fabric bracelet that continually measures your child's
           perspiration level and body temperature. We would like to use the Qsensor® to determine
           whether or not IGF-1 improves these symptoms.

           .
    

Detailed Description

      There are two treatment periods in the trial. The multiple ascending dose (MAD) period is an
      intensive 4-week pharmacokinetic study which will require 3 inpatient stays and 4 half-day
      outpatient visits. During in-patient sessions, an IV line will be placed for frequent blood
      samples. A lumbar puncture will be performed by a physician at the beginning and again at the
      end of the MAD. The primary goal of the MAD is to determine the safety of IGF-1 therapy for
      girls with RTT. As such, the investigators will ask that you monitor your child's blood sugar
      levels using a glucometer. At the end of the MAD, you will have the option of enrolling your
      daughter in an additional 20 weeks of open-label IGF-1 treatment.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Adverse Events

Secondary Outcome

 Change From Pre-MAD Apnea Index at Post-OLE

Condition

Rett Syndrome

Intervention

rhIGF-1

Study Arms / Comparison Groups

 rhIGF-1
Description:  Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the OLE.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

12

Start Date

December 2010

Completion Date

January 2013

Primary Completion Date

September 2012

Eligibility Criteria

        Inclusion Criteria:

          -  female

          -  with RTT (typical or variant) as defined using the internationally agreed 2010
             RettSearch criteria.

          -  genetically defined mutation or deletion of the MECP2 gene.

          -  Girls will have the following prepubertal status: (1) Tanner stage 1 or 2 breast
             development; (2) Tanner stage 1 or 2 pubic hair development; (3) and younger than 12
             years by bone age.

          -  Chronological age must be 2 years or older

        Exclusion Criteria:

          -  prior therapeutic use of IGF-1, growth hormone, Lupron® or sex steroids

          -  allergy to the trial product

          -  co-morbid or chronic illness beyond that known to be associated with Rett Syndrome:
             diabetes mellitus, fatty acid oxidation disorder, chromosomal aneuploidy, syndromes
             associated with high risk of malignancy, current or previous exposure to spinal
             irradiation or history of malignancy.

          -  severe scoliosis (defined as a spinal curve of 70 degrees or more as measured on
             clinical and radiological examination)
      

Gender

Female

Ages

2 Years - 12 Years

Accepts Healthy Volunteers

No

Contacts

Mustafa Sahin, MD, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01253317

Organization ID

10-08-0403


Responsible Party

Principal Investigator

Study Sponsor

Boston Children's Hospital

Collaborators

 International Rett Syndrome Foundation

Study Sponsor

Mustafa Sahin, MD, PhD, Principal Investigator, Boston Children's Hospital


Verification Date

June 2017